The overexpression of GPX8 is correlated with poor prognosis in GBM patients

Sibo Li, Xudong Jiang, Meicun Guan, Yi Zhang, Yanfei Cao, Lina ZhangFrontiers in Genetics 2022 · DOI

TL;DR

This study reveals that the protein GPX8 is significantly overexpressed in Glioblastoma (GBM), a highly aggressive brain cancer, and this overexpression is linked to a poorer prognosis for patients. The research suggests GPX8 plays a role in the transition of GBM cells towards a more aggressive mesenchymal state and influences the tumor's immune microenvironment, positioning it as a potential therapeutic target.

What Problem Does This Paper Address?

Glioblastoma (GBM) is the most common and deadliest primary brain tumor, characterized by high recurrence rates and poor patient survival, often less than two years. Despite advances in treatment, existing therapies have limited efficacy. While some genes are known to be associated with GBM's aggressive nature, the precise molecular mechanisms driving its progression and the identification of novel therapeutic targets remain critical challenges. This paper specifically investigates the role of Glutathione peroxidase 8 (GPX8), a protein previously linked to poor prognosis in other cancers, in GBM, aiming to understand its expression, function, and prognostic significance.

Methods

The researchers employed a multi-pronged approach to investigate GPX8's role in GBM:

  • Database Mining: They utilized several public databases (TCGA, CGGA, GEPIA, TIMER2.0, cBioPortal, GEO) to access and analyze gene expression data, patient survival data, and correlations with various biological processes and immune markers.
  • Experimental Validation:
    • Western Blotting: Used to confirm protein expression levels of GPX8 in GBM cell lines compared to normal astrocytes.
  • Immunohistochemistry (IHC): Employed to visualize and quantify GPX8 protein expression in glioma tissue samples of different grades.
  • Prognostic Analysis:
    • Kaplan-Meier Survival Analysis: To assess the relationship between GPX8 expression levels and overall survival (OS) in glioma patients.
  • Cox Regression Models: To determine if GPX8 is an independent prognostic factor for OS, considering other clinicopathological variables.
  • Functional Analysis:
    • Gene Ontology (GO) and Function Enrichment Analysis (Metascape): To identify biological pathways and cellular components associated with GPX8 and its co-expressed genes.
  • Gene Set Enrichment Analysis (GSEA): To investigate the enrichment of GPX8 in specific gene sets related to proneural-mesenchymal transition (PMT).
  • Correlation Analysis: To explore the relationship between GPX8 expression and PMT markers, as well as immune cell infiltration and signaling pathways within the GBM microenvironment.

Datasets

The study utilized publicly available datasets from the following sources:

  • TCGA (The Cancer Genome Atlas): A comprehensive repository of molecular and clinical data for various cancers, including GBM.
  • CGGA (Chinese Glioma Genome Atlas): A database specifically focused on glioma samples, providing transcriptomic and genomic data.
  • GEPIA (Gene Expression Profiling Interactive Analysis): A web server for analyzing RNA sequencing expression data from TCGA and GTEx.
  • TIMER2.0 (Tumor Immune Estimation Resource): A database for analyzing immune cell infiltration in various cancers.
  • cBioPortal for Cancer Genomics: A platform for exploring multidimensional cancer genomics data.
  • GEO (Gene Expression Omnibus): A public repository of high-throughput gene expression data.
  • GSE67089: A specific GEO dataset used for comparing mesenchymal and proneural glioblastoma stem cells.

Key Insights and Ideas

  • GPX8 as a Prognostic Indicator: The study strongly suggests that GPX8 is not just a marker but an independent prognostic factor for overall survival in glioma patients. This means its expression level, even when accounting for other known risk factors, provides significant predictive power.
  • The Proneural-Mesenchymal Transition (PMT) Link: A key finding is GPX8's association with the PMT process. The research indicates that higher GPX8 expression correlates with mesenchymal characteristics and negatively with proneural ones, suggesting GPX8 actively drives this transition, which is known to increase GBM's aggressiveness and therapy resistance.
  • GPX8 and the Immune Microenvironment: The study uncovers a complex relationship between GPX8 and the immune cells within the GBM tumor. GPX8 appears to influence the infiltration of various immune cells and is linked to key immune signaling pathways (like IL1/MYD88/IRAK/NF-κB), hinting at its role in modulating the tumor's immune response.
  • Therapeutic Potential: By identifying GPX8 as a key player in GBM progression and its association with poor prognosis, the research highlights it as a promising target for novel therapeutic strategies.

Key Results

  • Upregulation in GBM: GPX8 mRNA and protein levels were significantly upregulated in GBM tissues compared to normal brain tissues.
  • Prognostic Significance: High GPX8 expression was consistently associated with poorer overall survival across different WHO grades of glioma in both TCGA and CGGA datasets.
  • Independent Prognostic Factor: Cox regression analysis confirmed GPX8 as an independent prognostic factor for overall survival in high-grade glioma (HGG) patients.
  • PMT Association: GPX8 expression was positively correlated with mesenchymal markers (e.g., MET, VIM, CD44) and negatively with proneural markers (e.g., OLIG2, SOX2, CDH1). GSEA further supported GPX8's enrichment in mesenchymal signatures.
  • Immune Infiltration Correlation: GPX8 expression showed positive correlations with the infiltration of CD8+ T cells, CD4+ T cells, monocytes, neutrophils, myeloid dendritic cells, macrophages, and tumor-associated fibroblasts, while negatively correlating with plasma cells. It also correlated with MHC molecules, immunoinhibitors, and immunostimulators.

Limitations and Future Work

  • Direct PMT Evidence: While the study provides strong correlational evidence, it acknowledges that direct experimental evidence demonstrating GPX8's role in driving PMT is still lacking. Future work could involve in vitro and in vivo experiments to directly validate this mechanism.
  • Therapeutic Target Validation: The study proposes GPX8 as a therapeutic target. Further research is needed to develop and test specific inhibitors or modulators of GPX8 activity in preclinical models of GBM.
  • Mechanism of Immune Modulation: The precise mechanisms by which GPX8 influences the immune microenvironment require further elucidation. Understanding these interactions could lead to more targeted immunotherapeutic approaches.

Summary updated

Abstract

Glutathione peroxidase 8 (GPX8), located in the endoplasmic reticulum, is associated with poor prognosis in several cancers. However, the expression and functions of GPX8 in cancers remain unclear. The purpose of this study was to explore the expression and functions of GPX8 in glioblastoma (GBM). We obtained expression data of GPX8 by accessing the TCGA, CGGA, GEPIA, and TIMER2.0 databases and validated them using western blot and immunohistochemistry. The Kaplan-Meier overall survival curve and Cox regression model were used to evaluate the prognostic value of GPX8 in glioma patients. Gene ontology (GO) and function enrichment analysis were used to investigate the potential function of GPX8 in GBM. Correlation analysis was used to clarify the role of GPX8 in proneural-mesenchymal transition (PMT). We studied the correlation between GPX8 expression and GBM immune infiltration by accessing cBioPortal and TIMER2.0 databases. Here, we demonstrated that GPX8 was significantly upregulated in GBM, and was associated with IDH-wildtype and mesenchymal subtype with poor prognosis. Survival analysis results indicated that GPX8 is an independent prognostic factor for overall survival (OS) in all WHO-grade glioma patients. Through the functional studies, we found that high expression of GPX8 correlated with mesenchymal signature and negatively correlated with proneural signature, indicating that GPX8 might promote PMT in GBM. Finally, based on correlation analysis, we found that the expression of GPX8 was associated with immune infiltration and the IL1/MYD88/IRAK/NF-κB pathway in GBM. Our results show that GPX8 is a key factor affecting the prognosis of GBM patients, and its targeting has the potential to provide a novel therapeutic approach.
BibTeX
@inproceedings{li2022overexpression,
  author = {Sibo Li and Xudong Jiang and Meicun Guan and Yi Zhang and Yanfei Cao and Lina Zhang},
  title = {{The overexpression of GPX8 is correlated with poor prognosis in GBM patients}},
  booktitle = {Frontiers in Genetics},
  year = {2022},
  doi = {10.3389/fgene.2022.898204},
}
Figure